New drug combo shows promise in early cancer trial

NCT ID NCT03486301

Completed Disease control Sponsor: Eikon Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is complete, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BDB001 (an immunotherapy drug) and pembrolizumab (a drug that helps the immune system fight cancer)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is an early Phase 1 trial with only 87 participants, focused on safety and dosing. It is too small and early to know if the combination will be effective or safe for broader use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUMOR, SOLID

Contacts and locations

Locations

Atlantic Health

Morristown, New Jersey, 07960, United States
Florida Cancer Specialists

Sarasota, Florida, 34230, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
South Texas Accelerated Research Therapeutics (START)

San Antonio, Texas, 78229, United States
Tennessee Oncology

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.